Nisa Investment Advisors LLC increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 35.1% during the second quarter, Holdings Channel.com reports. The firm owned 16,858 shares of the biopharmaceutical company’s stock after acquiring an additional 4,378 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $2,497,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Oppenheimer Asset Management Inc. purchased a new position in Alnylam Pharmaceuticals in the 1st quarter worth $28,000. Exchange Traded Concepts LLC raised its position in Alnylam Pharmaceuticals by 84.1% in the 1st quarter. Exchange Traded Concepts LLC now owns 707 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 323 shares during the period. CWM LLC raised its position in Alnylam Pharmaceuticals by 19.3% in the 2nd quarter. CWM LLC now owns 656 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 106 shares during the period. Advisor Group Holdings Inc. purchased a new position in Alnylam Pharmaceuticals in the 1st quarter worth $159,000. Finally, D.A. Davidson & CO. purchased a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at about $210,000. Institutional investors own 92.95% of the company’s stock.
Shares of NASDAQ ALNY opened at $145.76 on Friday. The firm’s 50 day moving average price is $150.54 and its 200-day moving average price is $130.27. Alnylam Pharmaceuticals, Inc. has a 52-week low of $69.11 and a 52-week high of $167.33. The company has a current ratio of 4.68, a quick ratio of 4.48 and a debt-to-equity ratio of 0.20.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $0.27. The firm had revenue of $71.94 million for the quarter, compared to the consensus estimate of $90.45 million. Alnylam Pharmaceuticals had a negative net margin of 310.01% and a negative return on equity of 57.63%. The business’s revenue was up 173.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.42) earnings per share. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -6.17 earnings per share for the current year.
In other news, COO Yvonne Greenstreet sold 7,811 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $140.00, for a total transaction of $1,093,540.00. Following the completion of the transaction, the chief operating officer now directly owns 11,070 shares of the company’s stock, valued at $1,549,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Barry E. Greene sold 22,265 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $149.99, for a total transaction of $3,339,527.35. Following the transaction, the president now directly owns 84,501 shares of the company’s stock, valued at $12,674,304.99. The disclosure for this sale can be found here. In the last quarter, insiders sold 145,592 shares of company stock worth $22,374,942. Insiders own 3.50% of the company’s stock.
A number of equities analysts have issued reports on the stock. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 20th. Piper Sandler decreased their price objective on shares of Alnylam Pharmaceuticals from $147.00 to $142.00 in a research report on Tuesday, April 14th. UBS Group boosted their price objective on shares of Alnylam Pharmaceuticals from $111.00 to $122.00 and gave the company a “neutral” rating in a research report on Thursday, May 28th. BMO Capital Markets boosted their price objective on shares of Alnylam Pharmaceuticals from $173.00 to $196.00 and gave the company an “outperform” rating in a research report on Monday, July 20th. Finally, ValuEngine cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $151.74.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Featured Story: How to use beta for portfolio diversification
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.